Sales & Marketing News | pharmaphorum

News

Biogen updates on its confirmatory Aduhelm trial

Biogen and partner Eisai have said they will provide details next March for the confirmatory trial that will be needed to upgrade the drug's accelerated approval for controversial Alzheimer

News

BMS' Orencia gets FDA nod for GvHD thanks to real-world data

Bristol-Myers Squibb's rheumatoid arthritis drug Orencia has been approved by the FDA to prevent graft versus host disease (GvHD), a serious complication of haematopoietic stem cell transpl

News

Australia's CSL makes $11.7bn bid for Swiss pharma Vifor

Australian biotech group CSL has agreed a deal to acquire Swiss drugmaker Vifor Pharma in an all-cash deal that expands its speciality medicines business.

News

AbbVie prices first presbyopia drug Vuity at $80 per month

AbbVie has ended speculation about what it will charge for its newly-approved Vuity therapy for presbyopia, a sight condition characterised by difficulty in focusing on near objects.

News

Shkreli's former company pays $40m in price-gouging settleme...

A pharma company formerly led by 'pharma bro' Martin Shkreli has settled a long-running lawsuit with the US federal government over massive price increases for an off-patent drug treatment

News

Did AZ scupper Sobi's $8bn private equity buyout?

An $8 billion attempt by two private equity companies to acquire Swedish rare disease specialist Sobi and take it back into private ownership has collapsed, with reports suggesting AstraZen

Biogen updates on its confirmatory Aduhelm trial

BMS' Orencia gets FDA nod for GvHD thanks to real-world data

Australia's CSL makes $11.7bn bid for Swiss pharma Vifor

AbbVie prices first presbyopia drug Vuity at $80 per month

Shkreli's former company pays $40m in price-gouging settleme...

Did AZ scupper Sobi's $8bn private equity buyout?

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks